Merck in Advanced Talks to Buy Seagen in Nearly US$ 40 Billion Deal

KONTAN.CO.ID - Drugmaker Merck & Co is in advanced talks to buy cancer-focused biotech company Seagen Inc in a deal that could be worth roughly US$ 40 billion or more. The Wall Street Journal reported on Wednesday.
The companies are discussing a price above US$ 200 a share for Seagen, the report said, citing people familiar with the matter.
Ini Artikel Spesial
Agar bisa lanjut membaca sampai tuntas artikel ini, pastikan Anda sudah berlangganan.
Sudah berlangganan? MasukBerlangganan dengan Google
Gratis uji coba 7 hari pertama. Anda dapat menggunakan akun Google sebagai metode pembayaran.
Kontan Digital Premium Access
Business Insight, Epaper Harian + Tabloid, Arsip Epaper 30 Hari
Rp 120.000
Business Insight
Hanya dengan 20rb/bulan Anda bisa mendapatkan berita serta analisis ekonomi bisnis dan investasi pilihan